Nuvation Bio Inc (NYSE: NUVB)’s stock price has soared by 11.08 in relation to previous closing price of 2.12. Nevertheless, the company has seen a gain of 2.39% in its stock price over the last five trading days. businesswire.com reported 2025-05-21 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking.
Is It Worth Investing in Nuvation Bio Inc (NYSE: NUVB) Right Now?
NUVB has 36-month beta value of 1.37. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVB is 226.75M, and currently, short sellers hold a 16.68% ratio of that float. The average trading volume of NUVB on June 02, 2025 was 3.53M shares.
NUVB’s Market Performance
NUVB stock saw an increase of 2.39% in the past week, with a monthly gain of 3.74% and a quarterly increase of 29.40%. The volatility ratio for the week is 3.73%, and the volatility levels for the last 30 days are 5.28% for Nuvation Bio Inc (NUVB). The simple moving average for the past 20 days is 7.20% for NUVB’s stock, with a -2.96% simple moving average for the past 200 days.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Citizens JMP repeating the rating for NUVB by listing it as a “Mkt Outperform.” The predicted price for NUVB in the upcoming period, according to Citizens JMP is $6 based on the research report published on April 23, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $10, previously predicting the price at $1.40. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 27th, 2024.
BTIG Research gave a rating of “Buy” to NUVB, setting the target price at $5 in the report published on March 26th of the previous year.
NUVB Trading at 14.88% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Liu Dongfang, who sale 20,000 shares at the price of $2.50 back on May 02 ’25. After this action, Liu Dongfang now owns 12,000 shares of Nuvation Bio Inc, valued at $50,024 using the latest closing price.
DONGFANG LIU , the Officer of Nuvation Bio Inc, proposed sale 20,000 shares at $2.27 during a trade that took place back on May 02 ’25, which means that DONGFANG LIU is holding shares at $45,400 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -18.83 for the present operating margin
- 0.14 for the gross margin
The net margin for Nuvation Bio Inc stands at -55.34. The total capital return value is set at -0.47. Equity return is now at value -119.66, with -109.69 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -10.05. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -719.03.
Currently, EBITDA for the company is -566.91 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 69.58. The receivables turnover for the company is 2.01for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.01.
Conclusion
To put it simply, Nuvation Bio Inc (NUVB) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
